Shanghai Hile Bio-tech (603718) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-1.18 Million ≈ $-173.40K USD) by net assets (CN¥1.70 Billion ≈ $248.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 603718 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Shanghai Hile Bio-tech - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Shanghai Hile Bio-tech's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shanghai Hile Bio-tech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Hile Bio-tech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RideNow Group, Inc.
NASDAQ:RDNW
|
-0.608x |
|
Sappe Public Company Limited
BK:SAPPE
|
0.070x |
|
Hynar Water Group Co. Ltd.
SHE:300961
|
N/A |
|
Joyvio Agriculture Development Co Ltd
SHE:300268
|
-0.016x |
|
Nerdwallet Inc
NASDAQ:NRDS
|
0.106x |
|
Wanxiang Doneed Co Ltd
SHG:600371
|
-0.012x |
|
JNK India Ltd
NSE:JNKINDIA
|
0.018x |
|
Avalo Therapeutics Inc
NASDAQ:AVTX
|
-0.179x |
Annual Cash Flow Conversion Efficiency for Shanghai Hile Bio-tech (2011–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Hile Bio-tech from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Shanghai Hile Bio-tech worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥895.97 Million ≈ $131.11 Million |
CN¥58.83 Million ≈ $8.61 Million |
0.066x | +140.65% |
| 2024-12-31 | CN¥1.70 Billion ≈ $249.23 Million |
CN¥46.47 Million ≈ $6.80 Million |
0.027x | +1190.98% |
| 2023-12-31 | CN¥1.17 Billion ≈ $171.91 Million |
CN¥-2.94 Million ≈ $-429.95K |
-0.003x | -100.95% |
| 2022-12-31 | CN¥1.11 Billion ≈ $162.57 Million |
CN¥292.91 Million ≈ $42.86 Million |
0.264x | +496.48% |
| 2021-12-31 | CN¥987.19 Million ≈ $144.46 Million |
CN¥43.63 Million ≈ $6.38 Million |
0.044x | -74.64% |
| 2020-12-31 | CN¥962.20 Million ≈ $140.80 Million |
CN¥167.68 Million ≈ $24.54 Million |
0.174x | +191.93% |
| 2019-12-31 | CN¥992.57 Million ≈ $145.24 Million |
CN¥59.25 Million ≈ $8.67 Million |
0.060x | +223.68% |
| 2018-12-31 | CN¥1.03 Billion ≈ $150.10 Million |
CN¥18.92 Million ≈ $2.77 Million |
0.018x | -43.23% |
| 2017-12-31 | CN¥1.07 Billion ≈ $157.29 Million |
CN¥34.92 Million ≈ $5.11 Million |
0.032x | -69.87% |
| 2016-12-31 | CN¥1.01 Billion ≈ $147.11 Million |
CN¥108.39 Million ≈ $15.86 Million |
0.108x | -48.51% |
| 2015-12-31 | CN¥963.31 Million ≈ $140.96 Million |
CN¥201.69 Million ≈ $29.51 Million |
0.209x | +6.09% |
| 2014-12-31 | CN¥558.50 Million ≈ $81.73 Million |
CN¥110.22 Million ≈ $16.13 Million |
0.197x | -33.07% |
| 2013-12-31 | CN¥500.66 Million ≈ $73.26 Million |
CN¥147.63 Million ≈ $21.60 Million |
0.295x | +12.64% |
| 2012-12-31 | CN¥467.89 Million ≈ $68.47 Million |
CN¥122.48 Million ≈ $17.92 Million |
0.262x | -29.01% |
| 2011-12-31 | CN¥405.74 Million ≈ $59.37 Million |
CN¥149.61 Million ≈ $21.89 Million |
0.369x | -- |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more